Neuroscientific Biopharmaceuticals Ltd.

As of June 30, 2026, Neuroscientific Biopharmaceuticals Ltd. carries a market capitalization of 22.99M, placing it among publicly traded companies globally. Its enterprise value stands at 18.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Neuroscientific Biopharmaceuticals Ltd. has 389.72M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Neuroscientific Biopharmaceuticals Ltd. maintains a current ratio of 14.27, meaning it holds 14.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.59, indicating moderate leverage, while an interest coverage ratio of -1,071.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neuroscientific Biopharmaceuticals Ltd. posted a negative return on equity (ROE) of -29.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.20, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Neuroscientific Biopharmaceuticals Ltd.'s stock has declined approximately 58.57% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.09.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -3.93M, while operating income came in at -5.11M.

As of June 30, 2026, Neuroscientific Biopharmaceuticals Ltd. holds 4.63M in cash and equivalents against 87,039.00 in total debt, resulting in a net debt position of -2.63M. Total book value stands at 14.81M, with working capital of 4.46M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 0.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Neuroscientific Biopharmaceuticals Ltd. shareholders.